Helio Genomics has announced a new partnership with Syneos Health to expand the commercialization of its HelioLiver test, a blood-based assay for the early detection of hepatocellular carcinoma.
By leveraging Syneos Health’s extensive experience in building and executing commercial programs, Helio aims to accelerate healthcare provider engagement and broad market adoption across the country.
The HelioLiver test utilizes artificial intelligence to analyze cell-free DNA methylation patterns, protein biomarkers, and patient demographics.
This collaboration builds upon Helio’s existing commercial distribution strategies, which include previous partnerships with Fulgent Genetics and Quest Diagnostics. Financial terms of the newly formed agreement have not been disclosed.
View source version on albertvilella.substack.com